Goldman Sachs resumed coverage of Roivant Sciences (ROIV) with a Buy rating and $19 price target The firm is positive on a successful clinical outcome for the Phase 3 VALOR data.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- Roivant Sciences participates in a conference call with JPMorgan
- Roivant Sciences Announces $500M Share Repurchase Program
- Roivant Sciences announces $500M share repurchase program
- Optimistic Outlook for Roivant Sciences: Buy Rating Backed by Brepo’s Potential and Financial Opportunities
- Optimistic Outlook for Roivant Sciences Driven by Promising Brepocitinib Results in Phase 3 VALOR Study